BamSEC and AlphaSense Join Forces
Learn More

Ultragenyx Pharmaceutical Inc.

NASDAQ: RARE    
Share price (1/8/25): $43.65    
Market cap (1/8/25): $4.031 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 14 pages Ultragenyx Pharmaceutical Inc. Amended and Restated 2023 Incentive Plan
12/34/56
EX-10.36
from 10-K 4 pages Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan Restricted Stock Unit Agreement
12/34/56
EX-10.35
from 10-K 5 pages Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan Non-Statutory Stock Option Agreement
12/34/56
EX-10.34
from 10-K 4 pages Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan Restricted Stock Unit Agreement
12/34/56
EX-10.33
from 10-K 5 pages Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan Non-Statutory Stock Option Agreement
12/34/56
EX-10.32
from 10-K 4 pages Name: Number of Restricted Stock Units Subject to Award: Date of Grant
12/34/56
EX-10.31
from 10-K 6 pages Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan Non-Statutory Stock Option Agreement
12/34/56
EX-10.30
from 10-K 6 pages Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan Incentive Stock Option Agreement
12/34/56
EX-10.18
from 10-K 30 pages Preamble Whereas, Ugx Is a Company Engaged in the Pharmaceutical Field Focusing on Development of RARE Disease Therapies and Has Obtained Regulatory Approval to Market Certain Medicinal Products Based on Active Pharmaceutical Ingredients; Whereas, Ioi Is a Supplier of Oleochemical Specialties for a Large Number of Pharmaceutical and Industrial Applications, Including the Development and Manufacturing of Drug Substance
12/34/56
EX-10.1
from 8-K 2 pages September 6, 2023 Howard Horn Re: Amendment No. 1 to Offer Letter Signature: /S/ Howard Horn Dated: September 6, 2023 1
12/34/56
EX-10.1
from 10-Q 7 pages Amendment No. 13 to Collaboration and License Agreement
12/34/56
EX-10.1
from 8-K 10 pages June 22, 2023 Re: Offer of Employment Compensation
12/34/56
EX-10
from 10-Q 4 pages May 1, 2023 Camille Bedrosian M.D. Re: Amendment No. 2 to Offer Letter Dear Camille
12/34/56
EX-10
from 10-Q 9 pages March 31, 2023 Re: Amended and Restated Offer of Employment
12/34/56
EX-10
from 10-Q 9 pages Ultragenyx Pharmaceutical Inc. 2014 Incentive Plan Performance Stock Unit Agreement
12/34/56
EX-10
from 10-K 80 pages Lease by and Between Brickbottom I Qozb LP Landlord and Ultragenyx Pharmaceutical Inc. Tenant 100 Chestnut Street Somerville, Massachusetts Note: See Subsection 6.1.9 for Provision Regarding Tenant’s Request for Landlord’s Consent to Alterations and Removal of the Alterations
12/34/56
EX-10
from 10-K 4 pages Third Amendment to Lease Agreement
12/34/56
EX-10
from 10-K 32 pages Commercial Master Service Agreement Between Ultragenyx Pharmaceutical Inc. 60 Leveroni Court Novato, Ca 94949 USA (Herein Known as “Ugx”) and Bsp Pharmaceuticals S.P.A. via Appia Km 65,561 04013 Latina Scalo (Lt), Italy (Herein Known as “Bsp”) Hereinafter Referred to Individually as a “Party” and Together as the “Parties”
12/34/56
EX-10.9
from 10-Q 4 pages Re: Amendment No. 1 to Offer Letter Dear John: On Behalf of Ultragenyx Pharmaceutical Inc. (The “Company”), I Am Pleased to Present to You This Amendment No. 1 (This “Amendment”), Which Amends the Offer of Employment Letter Agreement With You Dated June 11, 2015 (The “Offer Letter”) as Follows: 1. the Fourth Paragraph Under the Heading “Equity Grants” Is Hereby Deleted in Its Entirety. 2. the First Paragraph Under the Heading “Severance” in the Offer Letter Is Hereby Deleted in Its Entirety and Replaced With the Following
12/34/56
EX-10.8
from 10-Q 4 pages September 13, 2022 Erik Harris Re: Amendment No. 3 to Offer Letter Dear Erik
12/34/56